Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for XIST returned no results
Showing 1 to 15 of 1558 results for list

  1. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 9 February 2026.

    Technology appraisal guidance
    In consultation

  2. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.

    Technology appraisal guidance
    In consultation

  3. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 12 February 2026.

    Technology appraisal guidance
    In consultation

  4. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 20 February 2026.

    Technology appraisal guidance
    In consultation

  5. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 18 February 2026.

    Technology appraisal guidance
    In consultation

  6. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.

    Technology appraisal guidance
    In consultation

  7. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 19 February 2026.

    Technology appraisal guidance
    In consultation

  8. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

    In development Reference number: GID-TA10904 Expected publication date:  11 February 2026

    Technology appraisal guidance
    In development

  9. Type 2 diabetes in adults: management (medicines update)

    In development Reference number: GID-NG10336 Expected publication date:  18 February 2026

    NICE guideline
    In development

  10. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development Reference number: GID-TA11545 Expected publication date:  11 February 2026

    Technology appraisal guidance
    In development

  11. Blood transfusion - Tranexamic acid (update)

    In development Reference number: GID-NG10441 Expected publication date:  26 February 2026

    NICE guideline
    In development

  12. Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]

    In development Reference number: GID-TA11630 Expected publication date:  18 February 2026

    Technology appraisal guidance
    In development

  13. Medicines optimisation (QS120)

    This quality standard covers the safe and effective use of medicines. It covers people of all ages who are taking medicines, including those who are not getting the full benefit from their medicines. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    24 March 2016
    View quality statements

    Sections for QS120

  14. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]

    In development Reference number: GID-TA11675 Expected publication date:  18 February 2026

    Technology appraisal guidance
    In development

  15. Obinutuzumab with mycophenolate mofetil for treating lupus nephritis [ID6420]

    In development Reference number: GID-TA11478 Expected publication date:  12 February 2026

    Technology appraisal guidance
    In development